K. Yata

发表

Cell cycle analysis and expression of cell cycle regulator genes in myeloma cells overexpressing cyclin D1

T. Sugihara, J. Kurebayashi, K. Yata, 2001, British journal of haematology.

CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients

M. Hino, S. Kishida, N. Hosen, 2012, Leukemia.

Inhibition of TACE Activity Enhances the Susceptibility of Myeloma Cells to TRAIL

K. Yata, Toshio Matsumoto, M. Abe, 2012, PloS one.

Cell biological roles of IL-10 in myeloma cells

T. Sugihara, K. Yata, T. Otsuki, 2002 .

Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma

K. Yata, Toshio Matsumoto, S. Kagami, 2009, International journal of hematology.

of TNF-{alpha} converting enzyme (TACE) osteoclastogenesis through M-CSF receptor shedding by up-regulation GM-CSF and IL-4 induce dendritic cell differentiation and disrupt

K. Moriyama, K. Yata, Toshio Matsumoto, 2009 .

GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE).

K. Moriyama, K. Yata, Toshio Matsumoto, 2009, Blood.

Estrogen receptors in human myeloma cells.

J. Kurebayashi, K. Yata, T. Otsuki, 2000, Cancer research.

Anti‐HER2‐antibody enhances irradiation‐induced growth inhibition in head and neck carcinoma

J. Kurebayashi, K. Yata, T. Otsuki, 2001, International journal of cancer.

Targeting myeloma–osteoclast interaction with Vγ9Vδ2 T cells

K. Yata, Toshio Matsumoto, M. Abe, 2011, International journal of hematology.

TRAIL expression up-regulated by interferon-gamma via phosphorylation of STAT1 induces myeloma cell death.

T. Sugihara, K. Yata, T. Otsuki, 2006, Anticancer research.

Expression and production of interleukin 10 in human myeloma cell lines

J. Kurebayashi, K. Yata, H. Sakaguchi, 2000, British journal of haematology.

Cellular biological differences between human myeloma cell lines KMS-12-PE and KMS-12-BM established from a single patient.

K. Yata, A. Ueki, Y. Yawata, 2000, International journal of hematology.

IL-10 in Myeloma Cells

T. Sugihara, K. Yata, H. Sakaguchi, 2002, Leukemia & lymphoma.

Implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis

Kiyoshi Yoshida, T. Sugihara, K. Yata, 2006, American journal of hematology.

Establishment of CD7+ Human Myeloma Sister Cell Lines, KMS-21-PE and KMS-21-BM, Carrying t(11;14) and t(8;14)

M. Taniwaki, N. Nakazawa, K. Yata, 2001, Leukemia & lymphoma.

The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells

K. Yata, S. Yaccoby, 2004, Leukemia.

Expression of protein gene product 9·5 (PGP9·5)/ubiquitin‐C‐terminal hydrolase 1 (UCHL‐1) in human myeloma cells

T. Sugihara, K. Yata, Y. Sadahira, 2004, British journal of haematology.

KRN5500, a spicamycin derivative, exerts anti‐myeloma effects through impairing both myeloma cells and osteoclasts

K. Yata, Toshio Matsumoto, M. Abe, 2011, British journal of haematology.

Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.

M. Taniwaki, N. Nakazawa, J. Kurebayashi, 1999, International journal of oncology.

Effect of hypoxia on human seminoma cells.

Y. Jo, J. Kurebayashi, K. Yata, 2002, International journal of oncology.

Expression and In Vitro Modification of Parathyroid Hormone-Related Protein (PTHrP) and PTH/PTHrP-Receptor in Human Myeloma Cells

J. Kurebayashi, K. Yata, H. Sakaguchi, 2001, Leukemia & lymphoma.

Induction of differentiation in human marrow T cell precursors by the synthetic serum thymic factor, FTS.

R. Mertelsmann, K. Yata, J. Bach, 1980, Clinical and experimental immunology.

TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth

K. Yata, Toshio Matsumoto, M. Abe, 2010, PloS one.

Interleukin 10 abolishes the growth inhibitory effects of all‐trans retinoic acid on human myeloma cells

Y. Matsuo, T. Sugihara, J. Kurebayashi, 2002, British journal of haematology.

The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells

I. Endo, K. Yata, S. Nakamura, 2011, Leukemia.

[Aeromonas hydrophila septicemia with necrotizing myofascitis in a patient with hypoplastic leukemia].

T. Sugihara, K. Yata, Y. Yawata, 1999, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.

Synergistic Growth Inhibition of YM529 with Biologic Response Modifiers (BRMs) in Myeloma Cells

T. Sugihara, K. Yata, T. Otsuki, 2002, International journal of hematology.

Genetic and biological characterization of human myeloma cell lines: An overwiew of the lines established at Kawasaki Medical School

M. Taniwaki, N. Nakazawa, K. Yata, 2000 .

[Seven patients with stage I and II primary testicular lymphoma].

T. Sugihara, K. Yata, Y. Sadahira, 2002, [Rinsho ketsueki] The Japanese journal of clinical hematology.

KRN5500, a Spicamycin Derivative, Exerts Anti-Myeloma Effects through Impairing Both Myeloma Cells and Osteoclasts.

K. Yata, Toshio Matsumoto, M. Abe, 2008 .